Catalyst Pharmaceuticals Inc. (CPRX)
CPRX vs. UTHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two companies is the best option for those looking for undervalued stocks?
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics
Catalyst Pharmaceuticals (NASDAQ: CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a recent discussion with Barclays life sciences analyst Glen Santangelo. Chief Executive Officer Rich Daly also reviewed early commercial progress for Agamree in Duchenne muscular dystrophy (DMD), provided an update
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34%
The consensus price target hints at a 43.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy
Catalyst (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for March 4th
CPRX and XP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 4, 2026.
New Strong Buy Stocks for March 4th
ORN, LRCX, GMED, MYRG and CPRX have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2026.
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
Catalyst (CPRX) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
